Challenges of BCG-Unresponsive NMIBC

Key Takeaways

• BCG therapy resistance in bladder cancer patients is influenced by tumor biology, immune variability, and genetic factors, impacting prognosis negatively.
• Non-responders to BCG therapy often require alternative treatments, facing a poorer prognosis compared to responders.
• Current BCG shortages necessitate prioritizing high-risk patients and exploring alternative therapies, complicating patient management.
• The shortages underscore the need for new therapeutic options and improved supply chain management to ensure consistent patient care.